GMED
Price
$90.80
Change
+$0.33 (+0.36%)
Updated
Jan 17 closing price
Capitalization
7.19B
32 days until earnings call
POSC
Price
$1.11
Change
+$0.08 (+7.77%)
Updated
Jan 17 closing price
Capitalization
442.55K
Ad is loading...

GMED vs POSC

Header iconGMED vs POSC Comparison
Open Charts GMED vs POSCBanner chart's image
Globus Medical
Price$90.80
Change+$0.33 (+0.36%)
Volume$1.86M
Capitalization7.19B
Positron
Price$1.11
Change+$0.08 (+7.77%)
Volume$230.07K
Capitalization442.55K
GMED vs POSC Comparison Chart
Loading...
GMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
POSC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GMED vs. POSC commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Hold and POSC is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (GMED: $90.80 vs. POSC: $1.11)
Brand notoriety: GMED and POSC are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: GMED: 185% vs. POSC: 1379%
Market capitalization -- GMED: $7.19B vs. POSC: $442.55K
GMED [@Medical Specialties] is valued at $7.19B. POSC’s [@Medical Specialties] market capitalization is $442.55K. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GMED’s FA Score shows that 1 FA rating(s) are green whilePOSC’s FA Score has 1 green FA rating(s).

  • GMED’s FA Score: 1 green, 4 red.
  • POSC’s FA Score: 1 green, 4 red.
According to our system of comparison, both GMED and POSC are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GMED’s TA Score shows that 3 TA indicator(s) are bullish while POSC’s TA Score has 3 bullish TA indicator(s).

  • GMED’s TA Score: 3 bullish, 4 bearish.
  • POSC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GMED is a better buy in the short-term than POSC.

Price Growth

GMED (@Medical Specialties) experienced а +4.28% price change this week, while POSC (@Medical Specialties) price change was +7.77% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.97%. For the same industry, the average monthly price growth was +5.53%, and the average quarterly price growth was +1.10%.

Reported Earning Dates

GMED is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Medical Specialties (+0.97% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMED($7.19B) has a higher market cap than POSC($443K). GMED has higher P/E ratio than POSC: GMED (49.65) vs POSC (0.09). POSC (9.901) and GMED (9.781) have similar YTD gains . GMED has higher annual earnings (EBITDA): 347M vs. POSC (-699K). GMED has more cash in the bank: 518M vs. POSC (28K). POSC has less debt than GMED: POSC (962K) vs GMED (520M). GMED has higher revenues than POSC: GMED (1.57B) vs POSC (1.24M).
GMEDPOSCGMED / POSC
Capitalization7.19B443K1,623,476%
EBITDA347M-699K-49,642%
Gain YTD9.7819.90199%
P/E Ratio49.650.0956,748%
Revenue1.57B1.24M126,758%
Total Cash518M28K1,850,000%
Total Debt520M962K54,054%
FUNDAMENTALS RATINGS
GMED vs POSC: Fundamental Ratings
GMED
POSC
OUTLOOK RATING
1..100
4721
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
4041
SMR RATING
1..100
88100
PRICE GROWTH RATING
1..100
3958
P/E GROWTH RATING
1..100
3100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

POSC's Valuation (23) in the null industry is somewhat better than the same rating for GMED (87) in the Medical Specialties industry. This means that POSC’s stock grew somewhat faster than GMED’s over the last 12 months.

GMED's Profit vs Risk Rating (40) in the Medical Specialties industry is in the same range as POSC (41) in the null industry. This means that GMED’s stock grew similarly to POSC’s over the last 12 months.

GMED's SMR Rating (88) in the Medical Specialties industry is in the same range as POSC (100) in the null industry. This means that GMED’s stock grew similarly to POSC’s over the last 12 months.

GMED's Price Growth Rating (39) in the Medical Specialties industry is in the same range as POSC (58) in the null industry. This means that GMED’s stock grew similarly to POSC’s over the last 12 months.

GMED's P/E Growth Rating (3) in the Medical Specialties industry is significantly better than the same rating for POSC (100) in the null industry. This means that GMED’s stock grew significantly faster than POSC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GMEDPOSC
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 11 days ago
70%
Bullish Trend 11 days ago
78%
Momentum
ODDS (%)
Bullish Trend 11 days ago
70%
Bearish Trend 11 days ago
90%
MACD
ODDS (%)
Bullish Trend 11 days ago
65%
Bearish Trend 11 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 11 days ago
69%
Bullish Trend 11 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
65%
Bearish Trend 11 days ago
81%
Advances
ODDS (%)
Bullish Trend 13 days ago
68%
Bullish Trend about 1 month ago
67%
Declines
ODDS (%)
Bearish Trend 20 days ago
57%
Bearish Trend 16 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
69%
N/A
Aroon
ODDS (%)
Bearish Trend 11 days ago
56%
Bearish Trend 11 days ago
87%
View a ticker or compare two or three
Ad is loading...
GMED
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
POSC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VNSNX22.720.17
+0.75%
Natixis Vaughan Nelson Select N
RYFAX86.040.60
+0.70%
Rydex Financial Services H
GQESX33.050.15
+0.46%
GMO Quality R6
LVOLX18.020.03
+0.17%
SGI US Large Cap Equity A
USGRX23.96N/A
N/A
Victory Growth & Income

GMED and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMED has been loosely correlated with ATEC. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then ATEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMED
1D Price
Change %
GMED100%
+0.36%
ATEC - GMED
45%
Loosely correlated
+2.48%
OFIX - GMED
37%
Loosely correlated
+1.12%
MYGN - GMED
34%
Loosely correlated
-1.04%
FNA - GMED
34%
Loosely correlated
+2.06%
GKOS - GMED
32%
Poorly correlated
-0.08%
More

POSC and

Correlation & Price change

A.I.dvisor tells us that POSC and SLDX have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that POSC and SLDX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To POSC
1D Price
Change %
POSC100%
+7.77%
SLDX - POSC
27%
Poorly correlated
N/A
GMED - POSC
20%
Poorly correlated
+0.36%
RSMDF - POSC
9%
Poorly correlated
N/A
RSCF - POSC
8%
Poorly correlated
+8.17%
PFGTF - POSC
7%
Poorly correlated
N/A
More